Unipathic Medicine

Unipathic Medicine on the Cutting Edge of Lyme Disease Treatment

There are many methods that must be performed for a patient to overcome Lyme disease and its’ co-infections. The key to approaching Lyme disease is being aware of all of the complexities and being able to address them, using a unique medical blueprint with the best technologies from around the world. Traditional treatment with antibiotics is effective for early stages of Lyme disease, but it only scratches the surface when treating late-stage Lyme disease, or what Unipathic Medicine calls chronic Lyme disease. According to Medscape, “Patients with probable late Lyme disease, or those untreated patients with a positive IgG serologic test for Lyme disease and otherwise unexplained symptoms, represent an interesting subset of patients who have not been clinically characterized in the modern Lyme disease literature.” These patients need help, and Unipathic Medicine is on the cutting edge of Lyme disease treatment.

Testing is the first step in any chronic Lyme disease treatment plan. There are four main tests for Lyme disease that can be used by physicians. Unipathic Medicine considers the Western blot and Elisa tests superior, as most medical professionals will agree. However, these are insufficient, and we encourage physicians to also utilize PCR, immunological tests, as well as all co-infection tests (including viral, fungal, and parasitic).What is tricky is that sometimes there will be a false positive or a false negative when testing for Lyme disease, so symptoms are often a good indicator that the patient has Lyme disease. Those symptoms are bulls-eye rash (though not always), fatigue, body aches, stiffness, brain fog, painful and swollen joints, and possible heart problems.

An impediment to antibiotic treatment is biofilm. In Raphael Stricker’s research article about biofilm he finds: “These adherent polysaccharide-based matrices protect bacteria from the hostile host environment and facilitate persistent infection.” Biofilm presence complicates matters by protecting the Borrelia Lyme disease infection (bacteria). The good news is that Unipathic Medicine has anti-biofilm technology and combines it with advanced immunotherapy, aggressive natural antiviral, antifungal, IV antibiotics and biodetoxification. When this is provided to a properly trained integrative physician and administered as part of a customized treatment plan, these therapies can help bring patients back to optimal health.

In Lyme disease the nervous system and neurochemistry is disrupted because the infection directly disrupts the neuroendocrine and immune systems. Borrelia (Lyme disease) and its co-infections produce dangerous neurotoxins that block those receptors sites on the nerve cells prohibiting the correct function on the neurotransmitters. The situation is similar to a keyhole becoming blocked or jammed, not allowing the key to open up the door. Here the receptors become blocked and impaired by the bacteria lipoproteins and neurotoxins. As a result, the nerve cell function is impaired. This is essentially one of the main hurtles with Lyme disease neurochemistry – the neurotoxin progressed disease. A simple solution is amino acids; which can balance these neurotransmitters by feeding the pathways. The deficiencies are then addressed and physicians are now able to replenish patients with oral or even better IV amino acids, minerals and co-factors to help.

The final step for getting rid of neurotoxins is utilizing the biodetoxification process. Ultimately the neurotoxins are competing with every nerve and hormone receptor within the patient’s body; neurotoxins affect the neurotransmitters. When physicians balance them while treating all infections properly to include viral, fungal and parasitic factors, and remove chemical/environmental toxins and heavy metals in a customized complete treatment plan, patients see long term benefits. At the end of the treatment plan a patient should be given targeted IV antibiotics to finish off their Lyme disease infection.


[1] Aucott, John N, et all. “Probable Late Lyme Disease – A Variant Manifestation of Untreated Borrelia burgdorferi Infection.” BMC Infect Dis. 2012; 12(173). http://www.medscape.com/viewarticle/777018_2
[2] Stricker, Raphael B and Lorraine Johnson. “Lyme disease: the next decade.” Infect Drug Resist. 2011; 4: 1–9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108755/
January 25, 2017

0 Responses on Unipathic Medicine on the Cutting Edge of Lyme Disease Treatment"

Leave a Message

Copyright @ Unipathic Medicine 2017